Dettagli progetto


The global objective of the first call is to launch European Collaborative projects, providing innovative ICT based solutions for elderly persons with identified risks factors and/or chronic conditions. The call is timely as it targets chronic diseases related to the elderly population, which exert an increasing impact in the present society due to the longer expectancy of life.Such is the case of Parkinson’s Disease (PD), a pathology with a high impact in the healthcare systems, due to its chronic condition in patients living longer, jointly with the growing number of people suffering of it, which is thought to affect more than four million people world-wide. It is the fourth most frequent disorder of the nervous system, after epilepsy, brain vascular disease and Alzheimer. The average age at diagnosis is 60 years. WHO has estimated that the overall prevalence in Europe is 1.6 per 100 in people over 65 years. Given its rapidly advancing aging population, PD will undoubtedly become a major public health issue in Europe in the coming years.PD is a slowly progressive disorder of the central nervous system that affects movement, muscle control and balance. The disease affects worldwide about 1% of all adults over the age of 65, but frequently the clinical symptoms appear earlier. Although the exact cause of PD is unknown, research has concentrated on genetics, environmental toxins, endogenous toxins and viral infection. The disease originates from a deficiency in the release of dopamine owing to the cells destruction in part of the brain stem. By the time symptoms develop, patients have lost ≥60 percent of their dopamine-producing cells.The syndrome comprises three cardinal features: bradykinesia, muscular rigidity, resting tremor and postural instability. Additional symptoms that support diagnosis include unilateral onset and levodopa response. Patients can experience depression, sleep disturbances, dizziness and problems with speech, swallowing and sexual functioning.The progression of the disease varies from individual to individual, so treatment is also individualized. Treatment focuses on relieving disabilities while minimizing side effects of medications. While there is no cure, therapies can minimize symptoms and maximize function and quality of life.Parkinson's can impairs the length of life, so its diagnosis and symptoms can devastate an individual and family, and patients often face depression. Research on improvement of quality of life and symptom control of Parkinsonism is of primary importance.Chronic diseases were traditionally well controlled in hospital environments thanks to the balance between patients and resources. But a growing population and a lack of medical resources have made necessary an alternative way to face these diseases, not only at an individual level, but also for public and private health care plans in terms of cost effectiveness. This is even more relevant in PD, in which the typical symptoms including tremors as well as blockades, lead patients to severely handicap in their daily life activities.As the continuation of the successful FP6 funded project INTELLIDRUG, HELP will develop a system to dynamically monitorize and treat PD, composed of (a) an intra-oral electronic drug delivery device that is miniature, non-invasive and removable, (b) an external pump to deliver higher amounts of doses to keep basal level of drug on blood stable, c) a PAN (Personal Area Network) to gather user’s environment information to detect tremor and blockades, (d) a telecommunication and services infrastructure to analyze

Key findings

Data di inizio/fine effettiva6/1/096/1/12